A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma (Q46100102)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on June 1, 2011

Language	Label	Description	Also known as
English	A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma	scientific article published on June 1, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Heinz-Josef Lenz

6

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

author name string

Hagop Youssoufian

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Jayne Gurtler

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Karel Dicke

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Omar Kayaleh

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Mark Keaton

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Terry Katz

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Shaila Ballal

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Andrew H. Ko

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21629990

3 December 2024

Eric K. Rowinsky

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21629990

3 December 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21629990

3 December 2024

publication date

1 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

full work available at URL

https://link.springer.com/content/pdf/10.1007/s10637-011-9691-8.pdf

Portable Document Format

1 reference

10.1007/S10637-011-9691-8

https://api.crossref.org/works/10.1007/S10637-011-9691-8

3 December 2024

https://link.springer.com/article/10.1007/s10637-011-9691-8/fulltext.html

1 reference

10.1007/S10637-011-9691-8

https://api.crossref.org/works/10.1007/S10637-011-9691-8

3 December 2024

http://link.springer.com/content/pdf/10.1007/s10637-011-9691-8

1 reference

10.1007/S10637-011-9691-8

https://api.crossref.org/works/10.1007/S10637-011-9691-8

3 December 2024

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

30

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

1597-1606

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Pancreatic cancer: from molecular signature to target therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9691-8

21 January 2018

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/21629990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9691-8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21629990

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46100102&oldid=2283823379"